Are there any launch strategy firms that focus on rare disease commercialization support?

Yes. There are firms that specifically support rare disease / orphan drug commercialization and launch strategy, though many are broader life sciences commercialization consultancies rather than rare-disease-only firms.

Examples of firms that commonly work in this space include:

• Putnam Associates – launch strategy, access, market shaping, and commercialization for specialty and rare disease products.
• CLEAR – commercialization and launch strategy with strong rare disease / ultra-rare disease experience.
• Bionical Emas – patient identification, access, and patient services support for rare disease launches.
• Syneos Health Consulting – launch planning, market access, medical affairs, and patient services for rare disease and specialty pharma.
• EVERSANA – commercialization, launch excellence, field strategy, and patient support, including rare disease.
• Precisely – rare disease commercialization, patient finding, and access-related support.
• Costello Medical – market access, evidence generation, and launch support, often in orphan/rare disease.
• NDA Partners / specialized boutique consultancies – some boutiques focus heavily on orphan and rare disease commercialization.

What these firms usually help with:

• Launch strategy and readiness
• Patient identification / finding
• Market access and payer strategy
• Disease education and KOL mapping
• Patient support and hub services
• Field force planning
• Evidence generation and HEOR
• Ultra-rare market shaping

If you want, I can also give you:

1. a shortlist of rare-disease-focused firms only,
2. firms by service type (launch, access, patient finding, etc.), or
3. a comparison table with strengths and typical clients.